 Such information may suggest that ODM-201 be combined with other modalities; for example, if treatment with the drug is discovered to affect multiple signaling pathways. Molecular profiling of tumor samples before and after ODM-201 treatment may permit the identification of patients likely or unlikely to respond to the agent based on the biological and molecular characteristics of their tumors. 